PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis • PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Hormone therapy - Market size and forecast 2018-2023 • Analgesics - Market size and forecast 2018-2023 • Market opportunity by product PART 07: MARKET SEGMENTATION BY ROA PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS • Strategic alliances • Robust pipeline • Availability of patient-assistance programs PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AbbVie Inc. • Allergan Plc • AstraZeneca Plc • Bayer AG • Johnson & Johnson Services Inc. • Mayne Pharma Group Ltd. • Merck & Co., Inc. • Pfizer Inc. • Takeda Pharmaceutical Co. Ltd. • Teva Pharmaceutical Industries Ltd. PART 15: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors PART 16: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Hormone therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Hormone therapy - Year-over-year growth 2019-2023 (%) Exhibit 22: Analgesics - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Analgesics - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by product Exhibit 25: Market segmentation by RoA: Overview Exhibit 26: Customer landscape Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 30: North America - Year-over-year growth 2019-2023 (%) Exhibit 31: Top 3 countries in North America Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 33: Europe - Year-over-year growth 2019-2023 (%) Exhibit 34: Top 3 countries in Europe Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Asia - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in Asia Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 39: ROW - Year-over-year growth 2019-2023 (%) Exhibit 40: Top 3 countries in ROW Exhibit 41: Key leading countries Exhibit 42: Market opportunity Exhibit 43: Side effects of OCPs used for treatment of endometriosis Exhibit 44: Impact of drivers and challenges Exhibit 45: Drug development pipeline late-stage molecules for treatment of endometriosis Exhibit 46: Vendor landscape Exhibit 47: Landscape disruption Exhibit 48: Vendors covered Exhibit 49: Vendor classification Exhibit 50: Market positioning of vendors Exhibit 51: AbbVie Inc. - Vendor overview Exhibit 52: AbbVie Inc. - Business segments Exhibit 53: AbbVie Inc. - Organizational developments Exhibit 54: AbbVie Inc. - Geographic focus Exhibit 55: AbbVie Inc. - Key offerings Exhibit 56: AbbVie Inc. - Key customers Exhibit 57: Allergan Plc - Vendor overview Exhibit 58: Allergan Plc - Business segments Exhibit 59: Allergan Plc - Organizational developments Exhibit 60: Allergan Plc - Segment focus Exhibit 61: Allergan Plc - Key offerings Exhibit 62: Allergan Plc - Key customers Exhibit 63: AstraZeneca Plc - Vendor overview Exhibit 64: AstraZeneca Plc - Business segments Exhibit 65: AstraZeneca Plc - Organizational developments Exhibit 66: AstraZeneca Plc - Geographic focus Exhibit 67: AstraZeneca Plc - Key offerings Exhibit 68: AstraZeneca Plc - Key customers Exhibit 69: Bayer AG - Vendor overview Exhibit 70: Bayer AG - Business segments Exhibit 71: Bayer AG - Organizational developments Exhibit 72: Bayer AG - Geographic focus Exhibit 73: Bayer AG - Segment focus Exhibit 74: Bayer AG - Key offerings Exhibit 75: Bayer AG - Key customers Exhibit 76: Johnson & Johnson Services, Inc. - Vendor overview Exhibit 77: Johnson & Johnson Services, Inc. - Business segments Exhibit 78: Johnson & Johnson Services, Inc. - Organizational developments Exhibit 79: Johnson & Johnson Services, Inc. - Geographic focus Exhibit 80: Johnson & Johnson Services, Inc. - Segment focus Exhibit 81: Johnson & Johnson Services, Inc. - Key offerings Exhibit 82: Johnson & Johnson Services, Inc. - Key customers Exhibit 83: Mayne Pharma Group Ltd. - Vendor overview Exhibit 84: Mayne Pharma Group Ltd. - Business segments Exhibit 85: Mayne Pharma Group Ltd. - Organizational developments Exhibit 86: Mayne Pharma Group Ltd. - Geographic focus Exhibit 87: Mayne Pharma Group Ltd. - Segment focus Exhibit 88: Mayne Pharma Group Ltd. - Key offerings Exhibit 89: Mayne Pharma Group Ltd. - Key customers Exhibit 90: Merck & Co. Inc. - Vendor overview Exhibit 91: Merck & Co. Inc. - Business segments Exhibit 92: Merck & Co. Inc. - Organizational developments Exhibit 93: Merck & Co. Inc. - Geographic focus Exhibit 94: Merck & Co. Inc. - Segment focus Exhibit 95: Merck & Co. Inc. - Key offerings Exhibit 96: Merck & Co. Inc. - Key customers Exhibit 97: Pfizer Inc. - Vendor overview Exhibit 98: Pfizer Inc. - Business segments Exhibit 99: Pfizer Inc. - Organizational developments Exhibit 100: Pfizer Inc. - Geographic focus Exhibit 101: Pfizer Inc. - Segment focus Exhibit 102: Pfizer Inc. - Key offerings Exhibit 103: Pfizer Inc. - Key customers Exhibit 104: Takeda Pharmaceutical Co. Ltd. - Vendor overview Exhibit 105: Takeda Pharmaceutical Co. Ltd. - Business segments Exhibit 106: Takeda Pharmaceutical Co. Ltd. - Organizational developments Exhibit 107: Takeda Pharmaceutical Co. Ltd. - Geographic focus Exhibit 108: Takeda Pharmaceutical Co. Ltd. - Key offerings Exhibit 109: Takeda Pharmaceutical Co. Ltd. - Key customers Exhibit 110: Teva Pharmaceutical Industries Ltd. - Vendor overview Exhibit 111: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 112: Teva Pharmaceutical Industries Ltd. - Organizational developments Exhibit 113: Teva Pharmaceutical Industries Ltd. - Segment focus Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 115: Teva Pharmaceutical Industries Ltd. - Key customers Exhibit 116: Validation techniques employed for market sizing Exhibit 117: Definition of market positioning of vendors

AbbVie Inc. Allergan Plc AstraZeneca Plc Bayer AG Johnson & Johnson Services Inc. Mayne Pharma Group Ltd. Merck & Co., Inc. Pfizer Inc. Takeda Pharmaceutical Co. Ltd. Teva Pharmaceutical Industries Ltd